EUVIMEDEUVIMED entdecken
Crossref

Serum Alpha and Beta‐CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor

Gabriel Gárate, Vicente González-Quintanilla, Andrea González, Marta Pascual, Sara Pérez-Pereda, Jorge Madera, Julio Pascual iD

Annals of Neurology · 2023-08 · 94 (2) · 285-294

DOI: 10.1002/ana.26658 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 21.04.2023. Verfasst von Gabriel Gárate und 6 weiteren Autor:innen. Beteiligte Einrichtung: Service of Neurology of the University Hospital Marqués de Valdecilla, Santander, Spain. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Eli Lilly and Company, Instituto de Investigación Marqués de Valdecilla, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of this study was to analyze the evolution of alpha and beta‐CGRP circulating levels throughout CGRP monoclonal antibodies (mAbs) treatment in patients with chronic migraine (CM).

Methods

We recruited patients with CM beginning mAbs along with sex and age paired healthy controls (HCs). Blood was extracted before, 2 weeks (M0.5) and 3 months (M3) after the first dose of mAbs, always in free‐migraine periods, and once for HCs. Alpha and beta‐CGRP serum levels were measured using enzyme‐linked immunosorbent assays (ELISAs) specific for each isoform.

Results

Baseline alpha‐CGRP levels were significantly elevated in 103 patients with CM (median = 50.3, 95% confidence interval [CI] = 40.5–57.0 pg/ml) compared to 78 HCs (median = 37.5, 95% CI = 33.9–45.0 pg/ml; 95% CI of differences = 2.85–17.08 pg/ml) and significantly decreased (n = 96) over the course of mAb treatment (M0.5: median = 40.4, 95% CI = 35.6–48.2 pg/ml; and M3: median = 40.9, 95% CI = 36.3–45.9 pg/ml). Absolute decrease of alpha‐CGRP throughout the treatment positively correlated with the decrease in MMDs. Negative modulation of alpha‐CGRP significantly associated with positive scores at the Patient Global Impression of Change scale and with analgesic overuse reversal. Beta‐CGRP did not differ at baseline between patients with CM (median = 4.2, 95% CI = 3.0–4.8 pg/ml) and HCs (median = 4.4, 95% CI = 3.4–5.6 pg/ml; −1.09 to 0.60) nor was modulated by mAb treatment (n = 96; M0.5: median = 4.5, 95% CI = 3.5–5.2 pg/ml; and M3: median = 4.6, 95% CI = 3.7–5.2 pg/ml).

Interpretation

Treatment with mAbs, regardless of its target, is able to progressively normalize basally increased alpha‐CGRP levels in CM and this effect correlates with efficacy measures, which supports a role of this neuropeptide as the first CM biomarker. ANN NEUROL 2023;94:285–294

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related PeptideMigraine DisordersHumansAntibodies, MonoclonalBiomarkers

Substanzen

Calcitonin Gene-Related PeptideAntibodies, MonoclonalBiomarkers

Autor:innen und Institutionen

  • Service of Neurology of the University Hospital Marqués de Valdecilla, Santander, Spain.
  • Instituto de Investigación Valdecilla, IDIVAL, Santander, Spain.
  • Universidad de Cantabria, Santander, Spain.
  • Service of Gastroenterology of the University Hospital Marqués de Valdecilla, Santander, Spain.

ORCID-Profile: Julio Pascual

Förderung

  • Eli Lilly and Company
  • Instituto de Investigación Marqués de Valdecilla
  • Instituto de Salud Carlos III

Zitieren

APA

Gárate, G., González-Quintanilla, V., González, A., Pascual, M., Pérez-Pereda, S., Madera, J., & Pascual, J. (2023). Serum Alpha and Beta‐CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor. Annals of Neurology, 94(2), 285-294. https://doi.org/10.1002/ana.26658

Vancouver

Gárate G, González-Quintanilla V, González A, Pascual M, Pérez-Pereda S, Madera J, et al. Serum Alpha and Beta‐CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor. Annals of Neurology. 2023;94(2):285-294. doi:10.1002/ana.26658

BibTeX
@article{Grate2023,
  author = {Gárate, Gabriel and González-Quintanilla, Vicente and González, Andrea and Pascual, Marta and Pérez-Pereda, Sara and Madera, Jorge and Pascual, Julio},
  title = {Serum Alpha and Beta‐CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor},
  journal = {Annals of Neurology},
  year = {2023},
  volume = {94},
  number = {2},
  pages = {285--294},
  doi = {10.1002/ana.26658}
}
Kostenlos starten →